Health-care companies rose amid enthusiasm about deal activity and obesity-drug sales.
Among the companies that are involved in deals, Novartis and GSK were higher. Investors also bought into obesity-drug makers including Novo Nordisk, which is now roughly 7% higher for 2024 so far.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
01-10-24 1739ET